全文获取类型
收费全文 | 2403篇 |
免费 | 159篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 59篇 |
妇产科学 | 27篇 |
基础医学 | 242篇 |
口腔科学 | 70篇 |
临床医学 | 149篇 |
内科学 | 579篇 |
皮肤病学 | 60篇 |
神经病学 | 122篇 |
特种医学 | 47篇 |
外国民族医学 | 1篇 |
外科学 | 483篇 |
综合类 | 48篇 |
一般理论 | 4篇 |
预防医学 | 126篇 |
眼科学 | 146篇 |
药学 | 220篇 |
中国医学 | 60篇 |
肿瘤学 | 121篇 |
出版年
2023年 | 23篇 |
2022年 | 40篇 |
2021年 | 141篇 |
2020年 | 66篇 |
2019年 | 117篇 |
2018年 | 92篇 |
2017年 | 74篇 |
2016年 | 66篇 |
2015年 | 69篇 |
2014年 | 133篇 |
2013年 | 127篇 |
2012年 | 197篇 |
2011年 | 183篇 |
2010年 | 101篇 |
2009年 | 74篇 |
2008年 | 117篇 |
2007年 | 143篇 |
2006年 | 136篇 |
2005年 | 116篇 |
2004年 | 132篇 |
2003年 | 106篇 |
2002年 | 87篇 |
2001年 | 18篇 |
2000年 | 34篇 |
1999年 | 21篇 |
1998年 | 10篇 |
1997年 | 3篇 |
1996年 | 8篇 |
1995年 | 6篇 |
1994年 | 8篇 |
1993年 | 6篇 |
1992年 | 8篇 |
1991年 | 12篇 |
1990年 | 14篇 |
1989年 | 13篇 |
1988年 | 8篇 |
1987年 | 13篇 |
1986年 | 19篇 |
1985年 | 7篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1974年 | 2篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有2578条查询结果,搜索用时 277 毫秒
71.
Arshad Mehmood Muhammad Ishaq Lei Zhao Bushra Safdar Ashfaq‐ur Rehman Masooma Munir Ali Raza Muhammad Nadeem Waheed Iqbal Chengtao Wang 《Chemical biology & drug design》2019,93(4):387-418
Hyperuricemia (HUA), a disease due to an elevation of body uric acid level and responsible for various diseases such as gout, cardiovascular disorders, and renal failure, is a major ground debate for the medical science these days. Considering the risk factors linked with allopathic drugs for the treatment of this disease, the debate has now become a special issue. Previously, we critically discussed the role of dietary polyphenols in the treatment of HUA. Besides dietary food plants, many researchers figure out the tremendous effects of medicinal plants‐derived phytochemicals against HUA. Keeping in mind all these aspects, we reviewed all possible managerial studies related to HUA through medicinal plants (isolated compounds). In the current review article, we comprehensively discussed various bioactive compounds, chemical structures, and structure–activity relationship with responsible key enzyme xanthine oxidase. 相似文献
72.
73.
Mehmood S Domene C Forest E Jault JM 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(27):10832-10836
The study of membrane proteins remains a challenging task, and approaches to unravel their dynamics are scarce. Here, we applied hydrogen/deuterium exchange (HDX) coupled to mass spectrometry to probe the motions of a bacterial multidrug ATP-binding cassette (ABC) transporter, BmrA, in the inward-facing (resting state) and outward-facing (ATP-bound) conformations. Trypsin digestion and global or local HDX support the transition between inward- and outward-facing conformations during the catalytic cycle of BmrA. However, in the resting state, peptides from the two intracellular domains, especially ICD2, show a much faster HDX than in the closed state. This shows that these two subdomains are very flexible in this conformation. Additionally, molecular dynamics simulations suggest a large fluctuation of the Cα positions from ICD2 residues in the inward-facing conformation of a related transporter, MsbA. These results highlight the unexpected flexibility of ABC exporters in the resting state and underline the power of HDX coupled to mass spectrometry to explore conformational changes and dynamics of large membrane proteins. 相似文献
74.
75.
76.
Abdel-Wahab O Pardanani A Bernard OA Finazzi G Crispino JD Gisslinger H Kralovics R Odenike O Bhalla K Gupta V Barosi G Gotlib J Guglielmelli P Kiladjian JJ Noel P Cazzola M Vannucchi AM Hoffman R Barbui T Thiele J Van Etten RA Mughal T Tefferi A 《American journal of hematology》2012,87(5):562-568
Immediately after the annual scientific meeting of the American Society of Hematology (ASH), a select group of clinical and laboratory investigators in myeloproliferative neoplasms (MPN) is summoned to a post-ASH conference on chronic myeloid leukemia and the BCR-ABL1-negative MPN. The 6th such meeting occurred on December 13–14,2011, in La Jolla, California, USA, under the direction of its founder,Dr. Tariq Mughal. The current document is the first of two reports on this post-ASH event and summarizes the most recent preclinical and clinical advances in polycythemia vera, essential thrombocythemia,and primary myelofibrosis. 相似文献
77.
Background
Bivalirudin is an ultrashort acting direct thrombin inhibitor, which has been used in place of heparin in selected settings. We describe our preliminary experience with the use of bivalirudin in patients who required anticoagulation for a deep vein thrombosis, prosthetic heart valve, or hypercoagulable state but were felt to be at high risk for the use of heparin.Methods
Eight patients in our neurocritical care unit required anticoagulation but were felt to be poor candidates for heparin either due to heparin-induced thrombocytopenia or due to high risk for intracranial hemorrhage. A standard protocol was utilized for bivalirudin with a loading dose of 0.75 mg/kg followed by a continuous infusion of 0.15 mg/kg hr. Serial aPTT levels were checked on a routine basis to monitor therapeutic effect. The bivalirudin infusion was continued for a period of 2 days to 2 weeks prior to starting coumadin therapy.Results
These patients were in the early postoperative period (within 48 h) following craniotomy, had suffered a recent large hemispheric infarct with hemorrhagic conversion, or had presented with an acute intracerebral hemorrhage. In this small series of patients, no intracranial hemorrhagic complications were encountered. No patients demonstrated progressive systemic thrombotic issues while on bivalirudin.Conclusion
Based on these findings, bivalirudin may represent a reasonable alternative in patients for whom heparin anticoagulation is contraindicated. A larger multicenter trial of bivalirudin in this setting may be appropriate 相似文献78.
Helen A. Fletcher Rachel Tanner Robert S. Wallis Joel Meyer Zita-Rose Manjaly Stephanie Harris Iman Satti Richard F. Silver Dan Hoft Beate Kampmann K. Barry Walker Hazel M. Dockrell Uli Fruth Lew Barker Michael J. Brennan Helen McShane 《Clinical and Vaccine Immunology : CVI》2013,20(11):1683-1689
Despite the widespread use of the Mycobacterium bovis BCG vaccine, there are more than 9 million new cases of tuberculosis (TB) every year, and there is an urgent need for better TB vaccines. TB vaccine candidates are selected for evaluation based in part on the detection of an antigen-specific gamma interferon (IFN-γ) response. The measurement of mycobacterial growth in blood specimens obtained from subjects immunized with investigational TB vaccines may be a better in vitro correlate of in vivo vaccine efficacy. We performed a clinical study with 30 United Kingdom adults who were followed for 6 months to evaluate the abilities of both a whole-blood- and a novel peripheral blood mononuclear cell (PBMC)-based mycobacterial growth inhibition assay to measure a response to primary vaccination and revaccination with BCG. Using cryopreserved PBMCs, we observed a significant improvement in mycobacterial growth inhibition following primary vaccination but no improvement in growth inhibition following revaccination with BCG (P < 0.05). Mycobacterial growth inhibition following primary BCG vaccination was not correlated with purified protein derivative (PPD) antigen-specific IFN-γ enzyme-linked immunospot (ELISPOT) responses. We demonstrate that a mycobacterial growth inhibition assay can detect improved capacity to control growth following primary immunization, but not revaccination, with BCG. This is the first study to demonstrate that an in vitro growth inhibition assay can identify a difference in vaccine responses by comparing both primary and secondary BCG vaccinations, suggesting that in vitro growth inhibition assays may serve as better surrogates of clinical efficacy than the assays currently used for the assessment of candidate TB vaccines. 相似文献
79.